中文
英文

Expert team

  • Lin Wenjie, Professor and Chief Scientist at Harvard University

    ·Founder of the World Ophthalmology Organization. The technological achievements include over 100 papers, including 7 published in the British journal Nature, 9 in the Proceedings of the National Academy of Sciences (PNAS), 2 in Scientific American, and 5 books on ophthalmology and neuroscience, as well as 17 international patents.
    ·In 1974, he became an associate professor at Harvard Medical School.
    ·In 2002, Professor Lin Wenjie's oral vaccine patent was selected by Time magazine as one of the top ten most important advances of the 21st century.
    ·In 2002, he was invited to serve as a member of the Academic Committee of the National Center for Life Sciences in China and an honorary professor at the University of Hong Kong.

  • Professor Zhou Lei, Chief Scientific Officer, Hong Kong Polytechnic University

    ·Top 2% of global scientists in the field of ophthalmology by 2024, professor at the School of Ophthalmology and Optometry and the Department of Applied Biotechnology at The Hong Kong Polytechnic University.
    ·PhD from the National University of Singapore, previously served as Senior Chief Research Scientist at the Singapore Institute of Ophthalmology, leading the Eye Proteomics Laboratory.
    ·Committed to applying cutting-edge mass spectrometry and proteomics/metabolomics technologies to biomedical research, taking the lead in comprehensive analysis of the human tear proteome and metabolome, and making significant progress in using tear proteins for disease diagnosis;
    ·Published 143 peer-reviewed papers and holds multiple international patents related to disease biomarkers, drug targets in angiogenesis, and antibacterial molecules.
    ·Served as a member of the board of directors of the Singapore Mass Spectrometry Society (VNet) from 2012 to 2023.
    ·In 2020, he was awarded the "Outstanding Achievement Award in Overseas Chinese Ophthalmology and Visual Science" by the Ophthalmology Branch of the Chinese Medical Association (COS).

  • Feng Yibin, Dean and Chief Scientific Officer of the School of Chinese Medicine at the University of Hong Kong

    ·Top 1% of global scientists in the field of traditional Chinese medicine by 2024.
    ·Professor, Doctor of Medicine, and Doctoral Supervisor at the School of Chinese Medicine, University of Hong Kong, who has long been active in the forefront of Chinese medicine education, clinical practice, and research,
    ·In 2012, served as the Executive Chairman of the 3rd International Medicinal Diet Therapy and the 3rd China Medicinal Diet Therapy Conference
    ·Served as Co Chair of the International Conference on Modern Traditional Chinese Medicine (ICMCM) for three sessions in 2013, 2018, and 2019
    ·Serving as a member of the Chinese Medicine Council of Hong Kong, a member of the Chinese Medicine Council of the Hospital Authority of Hong Kong, an expert in the registration review panel of Chinese patent medicines of the Chinese Medicine Council of Hong Kong, and an executive member of the Hong Kong Registered Chinese Medicine Association
    ·Serving as a guest professor at multiple domestic universities or research institutions, such as the Chutian Lecture Professor in Hubei Province, the Shennong Lecture Professor at Hubei Medical College, and a professor at the Key Laboratory of Natural Chemistry of the Chinese Academy of Sciences and Guizhou Province.

R&D Conversion Team

  • Professor Lin Zhushengzi is the patent holder for the herbal name moisturizing spray

    ·Director of the International Baccalaureate Institute (IAE) in the United States, Doctor of Oriental Medicine, and Visiting Professor at the Institute of Japanese Studies at Tamkang University in Taiwan.
    ·As the founder of Q-BIT optical quantum energy science and technology, she has made breakthrough progress in the field of photonics and holds licensed patents for related technologies.
    ·The president of Q-BIT Research Institute Co., Ltd. in Japan leads the institute's research and innovation in the field of photonics technology.

  • Yang Yuhan is a member of the doctoral research and development team

    ·PhD student at Hong Kong Polytechnic University, joint medical master's degree program between Guizhou Medical University and Fudan University
    ·Registered Ophthalmologist in China
    ·Familiar with the diagnosis and treatment of ophthalmic related diseases, proficient in various ophthalmic animal disease models, such as dry eye, ocular neovascularization, choroidal neovascularization, glaucoma, etc., possessing various ophthalmic cell culture techniques, such as primary extraction and culture of corneal stromal cells, corneal epithelial cell culture, umbilical vein endothelial cell culture, etc
    ·The current research direction mainly focuses on the development of dry eye biomarkers and the treatment of ocular surface diseases
    ·Published multiple SCI papers as first author and co author, with a total impact factor of 46.73

  • Wang Xinyue is a member of the doctoral research and development team

    ·The Hong Kong Polytechnic University is currently pursuing a doctoral degree, focusing on multi omics data analysis and possessing fundamental knowledge in bioinformatics and data science
    ·The current research direction is the proteomics and metabolomics of tears in eye diseases, aiming to understand the relationship between tear components and eye health and aging
    ·Published multiple SCI papers as the first author and co-author, with a total impact factor of 84.4

  • Zhang Linyi, a member of the master's research and development team

    ·Research Assistant at Hong Kong Polytechnic University
    ·Master's degree in Biotechnology from the National University of Singapore
    ·My research direction during my master's degree was proteomics research in atopic dermatitis
    ·At present, the main research direction is the application of mass spectrometry analysis (top-down proteomics) in eye diseases to search for new disease biomarkers and drug targets.

Strategic team

  • Professor Wang Ping, Founder and Chairman

    -Famous investor. Having over 25 years of experience in equity investment, mergers and acquisitions, and industrial fund management. Among them, over 50 equity investment projects have successfully gone public, and over 70 have successfully exited
    One.
    -Multiple times elected as the best local PE manager in China, multiple APEC business leaders representing the investment community, rotating chairman of the China Mergers and Acquisitions Association, permanent honorary chairman of the Hong Kong Fujian Federation of Associations, Davos
    Core member of the World Economic Forum.
    -We have unique expertise in strategic planning, positioning and layout, team optimization, corporate mergers and acquisitions, and capital operations. Our key investment and acquisition directions include big health and biomedicine, carbon neutrality, semiconductors, and more
    Digital economy, etc.
    -Investment cases: Nanwei Medical (688029), Edbio (300685), etc.

  • Dong Youqun, Co President

    -Chairman of Zhejiang Qianhong Industrial Co., Ltd. Vice Chairman of Huayu Win Win Double Group.
    -Started independently in 1995; From 2006 to the end of 2015, three Sino foreign joint venture shipbuilding companies were established and acquired. Invest in stone mines in the Yangtze River Delta construction market from 2016 to 2022.
    Since 2019, there has been a shift in capital investment, with a focus on the fields of big health and new energy. Nanjing Guobo Electronics Co., Ltd. was listed on the IPO on July 21, 2022. Finance at the beginning of 2020
    Wu invested in Fenghua Co., Ltd. and became the second largest shareholder as a concerted action person. In October 2020, Angel Investment invested in Jiangsu Xiechuang Energy Technology Co., Ltd. I have invested in Long since 2021
    A group of venture capital companies including Xinghang Electronics, Zhonggu Era New Energy, Huayongene Technology, Huaqing Electronics, Dingheng Shipping, Youneng New Energy, Knowledge Matrix, XunTeng Smart Technology, and Zhongwei Yixin.
    In 2022, acquire Beijing Qianzhou Qingyuan Investment Fund Management Co., Ltd. Strategic investment of 350 million yuan in a listed company in Shenzhen in April 2023

Commercialization team

  • Xing Kai, co-founder and CEO of Hong Kong company

    -Founding President of the Hong Kong Innovation and Technology Cooperation Promotion Association.
    -The EMBA program at Sofia University in the United States, CMA&IPA， Formerly served as a senior executive of Fortune 500 technology companies such as IBM and Siemens, a partner of China's first vertical incubation institution for new energy vehicle innovation technology, and former Executive Vice President of Shenzhen Terahertz Technology Innovation Research Institute, dedicated to the transformation and commercialization of Hong Kong's innovative scientific achievements.

  • Dr. Liu Huanming, Co President of Novo Longevity Hong Kong Company

    -I have been engaged in clinical work and biological experimental research for decades, studying under world-renowned doctors and professors, including Professor Hugh Taylor from Australia, Professor Arthur Lim from Singapore, and Professors Dennis Lam and CP Pang from Hong Kong.
    -Based on scientific research, we carefully select high-quality natural raw materials from around the world, and use unique formulas and innovative technology to create a series of high-quality and high-performance health products.

  • Gu Wanhong, Vice President and Chief Risk Officer CRO

    -Responsible for company risk control, President of Zhejiang Qianhong Industrial Co., Ltd.
    -I have been engaged in economic crime investigation work in public security organs for 25 years and am a provincial and municipal level economic investigation expert. I have extensive experience in the study of civil and criminal law intersection, as well as enterprise risk control and auditing

  • Xue Yinghua, Chief Financial Officer

    -Bachelor's and Master's degrees in Economics from Simon Fraser University in Canada;
    -With over 20 years of work experience, I have extensive experience in banking, finance, investment, and capital markets; Previously hired by the Hong Kong Stock Exchange to lead important projects such as consultation on the reform of the listing system and full circulation of H-shares.
    -Since 2020, led the development of a large EAM enterprise in Asia and served as the CFO of an information technology and cybersecurity company.
    -In 2022, invited to assist a boutique American investment bank in opening a new franchise in Hong Kong, focusing on business development, business partnerships, and transaction execution

  • Dr. James Li, Professor and Chief Consultant of Novo Longevity Hong Kong Company

    -Rotating President of the North American Society of Natural Medicine, Professor at the Canadian Health Institute, Executive Director of the European and American Intellectual Property Exchange, Partner of North American Element Capital, and President of the Global Barter Trade Center.

  • Professor Wen Huafen, President of Macau Kangzhi Mingshi Company

    -President of the Guangdong Hong Kong Macao Greater Bay Area Cultural Heritage Promotion Association, Chairman of the Zhuhai Network Industry Association, Member of the Medical and Health Committee of the Guangdong Hong Kong Macao Cooperation Promotion Association, Chairman of Macau Living Health, Director of International Yunbi Health Technology Co., Ltd., Chairman of Zhuhai Gongbei Yunbi Health Care Co., Ltd., and Director of Zhuhai Hengqin Aorui Medical Technology Co., Ltd
    -Honorary President of the World Federation of Chinese Entrepreneurs, Honorary President of the Desheng International Health Promotion Association
    -Vice President of Macau Health Association, member of the 5th World Health Beijing Conference.

  • Zhang Pingkang, President of Zhimingshi USA Company

    -In 2020, he was appointed as the General Manager of Green Leaf Company in the United States and concurrently served as the CFO of Green Leaf Company in Mexico, engaged in investment and securities business. Currently, he is pursuing a PhD at Fordham University.

  • Tang Poetry, Kang Zhiming, co-founder of Mingshi America Company

    -Founder of Worry Free Sleep, Partner of Lianhe Capital, Journalism major at Beijing Broadcasting Institute, EMBA program at Tsinghua University;
    -I have worked at China International Television as a program host and was a special guest of the CEO Reading Club. I am also the president of the American branch of the China Elite Association.

New Horizon Longevity Technology Co., Limited 

  • Address: Room 605, 6th Floor, General Commercial Building, 156-164 Des Voeux Road Central, Hong Kong

    在这里输入描述

Scan the code to view the official account

Copyright © 诺和⻓寿 support: 优河马